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T follicular helper (Tfh) cells provide help to B cells
and are crucial for establishment of germinal center
(GC) reactions, including production of high-affinity
antibodies and generation of memory B cells and
long-lived plasma cells. Here we report that the
magnitude of the Tfh cell response was dictated by
the amount of antigen and directly correlated with
the magnitude of the GC B cell response. In addition,
maintenance of the Tfh cell phenotype required sus-
tained antigenic stimulation byGCBcells. In lympho-
penic conditions, a strong and prolonged Tfh cell
response led to bystander B cell activation, hyper-
gammaglobulinemia, and production of poly- and
self-reactive antibodies. These data demonstrate
that antigen dose determines the size and duration
of the Tfh cell response and GC reaction, highlight
the transient nature of the Tfh cell phenotype, and
suggest a link between overstimulation of Tfh cells
and the development of dysregulated humoral
immune responses.
INTRODUCTION
T-cell-dependent antibody responses require the coordinated
interplay of many different cell types, including dendritic cells
(DCs), B cells, and T cells, in highly specialized secondary
lymphoid organ structures (Crotty, 2011; Goodnow et al., 2010;
McHeyzer-Williams et al., 2011). Whereas T cell activation in
the T cell zone is mediated by antigen-presenting DCs (Lanza-
vecchia and Sallusto, 2001), B cell activation in the follicle
involves directed transport of antigen by diffusion or cell-medi-
ated transport by B cells, macrophages, DCs, or follicular
dendritic cells, depending on the size of the antigen (Batista
and Harwood, 2009; Cyster, 2010). Within 1–3 days after initial
antigen encounter, activated T and B cells migrate to the T-B
zone border where they interact with each other (Vinuesa and
Cyster, 2011). Activated B cells then differentiate into either596 Immunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc.short-lived antibody-secreting cells forming extrafollicular foci
(MacLennan et al., 2003), or reenter the follicle to establish
germinal centers (GCs), the hallmark of T-cell-dependent anti-
body responses (Gatto and Brink, 2010; Victora and Nussenz-
weig, 2012). In these anatomical structures, B cells undergo
the processes of somatic hypermutation and affinity maturation,
leading to the differentiation of memory B cells and long-lived
plasma cells that produce high-affinity antibodies and eventually
migrate to the bone marrow (Good-Jacobson and Shlomchik,
2010; Goodnow et al., 2010; McHeyzer-Williams et al., 2011;
Tangye and Tarlinton, 2009).
T follicular helper cells (Tfh) have been described as a subset
of CD4+ T cells that are specialized in providing help to B cells,
being crucial for the development and regulation of GCs and
the establishment of serological memory (Crotty, 2011; King,
2009; McHeyzer-Williams et al., 2011; Vinuesa et al., 2010). Tfh
cells are defined by their expression of the chemokine receptor
CXCR5, which is required for migration toward the B cell
follicle-derived chemokine CXCL13 (Ansel et al., 1999; Breitfeld
et al., 2000; Kim et al., 2001; Schaerli et al., 2000). In addition,
Tfh cells express the costimulatory molecules ICOS and PD-1
(Haynes et al., 2007), secrete the B cell-trophic cytokine IL-21
(Nurieva et al., 2008; Vogelzang et al., 2008), and are character-
ized by the expression of the transcriptional repressor Bcl6
(Chtanova et al., 2004; Johnston et al., 2009; Nurieva et al.,
2009; Yu et al., 2009). DCs can prime human naive T cells to
differentiate into CXCR5+ Tfh cells (Langenkamp et al., 2003;
Ma et al., 2012), consistent with the finding in mice that BCL6
and CXCR5 can be induced in activated CD4+ T cells in vivo in
the absence of cognate interactions with B cells (Baumjohann
et al., 2011; Choi et al., 2011; Goenka et al., 2011; Kerfoot
et al., 2011; Kitano et al., 2011; Poholek et al., 2010). Neverthe-
less, B cells become the major antigen-presenting cell type for
follicle-homing T cells at later stages of the immune response
(Deenick et al., 2010; Haynes et al., 2007; Johnston et al.,
2009; Glatman Zaretsky et al., 2009) and interactions with GC
B cells might further polarize Tfh cells within the GC (Yusuf
et al., 2010). Although intravital 2-photon microscopy studies
have shown a dynamic behavior of Tfh cells in GCs (Allen
et al., 2007; Hauser et al., 2007; Qi et al., 2008; Schwickert
et al., 2007; Victora et al., 2010), how Tfh cells contribute to
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remains largely unknown. Here we showed that the amount
of antigen dictates the Tfh cell and GC B cell response, and
that maintenance of Tfh cells requires persistent antigen and
GC B cells. We also showed that strong and prolonged Tfh
cell responses can lead to bystander B cell activation, hyper-
gammaglobulinemia, and production of poly- and self-reactive
antibodies.
RESULTS
Tfh Cell and GC B Cell Numbers Are Highly Interrelated
and Positively Correlate with the Amount of Available
Antigen
In this study, we used classical adoptive transfer experiments in
which low numbers of naive ovalbumin (OVA)-specific CD4+
T cells from OT-II TCR-transgenic Rag-1-deficient mice were in-
jected into wild-type (WT) C57BL/6 mice (OT-II/WT) or into
Cd3e–/– mice (OT-II/Cd3e–/–) that lack all T cells but have
organized lymphoid organ structures and normal B cell develop-
ment (Malissen et al., 1995). In both groups of mice, a rapid
increase of OT-II cells was induced by intraperitoneal (i.p.) immu-
nization with OVA (see Figure S1A available online). Three weeks
after immunization, the number of OT-II cells declined in WT
hosts, whereas it continued to increase, albeit to a lower extent,
in Cd3e–/– hosts, most likely aided by the lymphopenic environ-
ment. OT-II cells recovered from both WT and Cd3e–/– mice
were homogeneously CD44hi and a proportion of them stained
positive for characteristic Tfh cell markers, including CXCR5,
PD-1, ICOS, BTLA, and CD69 (data not shown). Ex vivo sorted
CXCR5+ OT-II cells expressed the Tfh cell transcription factor
Bcl6 and Il21 (Figure S1B).
Using the above systems, we first analyzed the role of antigen
dose on the expansion of OT-II cell numbers and on their differ-
entiation into Tfh cells. OT-II/WT and OT-II/Cd3e–/– mice
were immunized i.p. with increasing doses of OVA in adjuvants,
and the spleen was analyzed on day +10 or day +14 by flow
cytometry. In WT hosts there was a slight, albeit nonsignificant,
increase in the total numbers of OT-II cells, whereas in Cd3e–/–
hosts total OT-II cell numbers progressively increased with the
dose of antigen administered (Figure 1A; Figure S1C). In both
OT-II/WT andOT-II/Cd3e–/– mice, the percentage of Tfh cells
(defined as PD-1+CXCR5+ or ICOS+CXCR5+) among OT-II cells
was significantly higher with increased amounts of available
antigen (Figure 1A; Figure S1C). The frequency of GC B cells
(defined as FAS+GL-7+ B cells) also progressively increased
with the dose of antigen administered (Figure 1B; Figure S1D).
Plotting total numbers of OT-II Tfh and GC B cells of each indi-
vidual mouse revealed a tight correlation between the two cell
types (Figure 1C; Figure S1E). In WT hosts, the correlation was
also observed for endogenous Tfh and GC B cells (data not
shown). In Cd3e–/– hosts, the total number of Tfh cells was on
average 5-fold higher than in WT hosts due to the larger expan-
sion of OT-II cells in the lymphopenic environment. It should
be noted that in Cd3e–/– hosts, OT-II cells did not vigorously
proliferate and did not acquire a Tfh cell phenotype when
the mice were immunized with a noncognate antigen, keyhole
limpet hemocyanin (KLH)+MPL, or injected with PBS alone
(Figure S1F).Next, we analyzed the impact of chronic antigenic stimulation
on the Tfh and GC B cell response. OT-II/WTmice were immu-
nized with NP-OVA+alum to elicit a robust Tfh and GC B cell
response; during the ensuing response, mice were injected
with either PBS as a control (acute stimulation) or several doses
of OVA protein in PBS (on day +4, +6, and +8, chronic stimula-
tion) to provide a constant supply of antigen; the spleen was
analyzed on day +9 by flow cytometry. Chronic antigenic stimu-
lation led to a significant expansion of OT-II cells and to a large
increase in the frequencies of PD-1+CXCR5+ Tfh cells and GC
B cells as compared to mice that had received only a single
NP-OVA+alum injection (Figure 1D). In chronic conditions,
more than 50% of OT-II cells coexpressed PD-1 and CXCR5.
Taken together, the above results, obtained in different
experimental systems, indicate that the magnitude of the Tfh
and GC B cell response is dictated by the amount of available
antigen and that Tfh and GC B cell numbers are highly
interrelated.
Antigen Is Required to Maintain the Tfh Cell Phenotype
To assess whether sustained antigenic stimulation was required
for the maintenance of Tfh cells, we used an adoptive transfer
system in which CD4+ TCR-tg T cells (SMARTA) specific for
LCMV carry a heterozygous YFP-BCL6 reporter allele (Kitano
et al., 2011) that allows for purification of viable CXCR5+BCL6+
Tfh cells. On day +4 following infection with LCMV, CXCR5+
YFP-BCL6hiPD-1hi Tfh and CXCR5–YFP-BCL6loPD-1int non-Tfh
SMARTA cells were isolated from primary hosts by cell
sorting and retransferred into secondary hosts, which had
been previously infected with LCMV or left untreated (Figure 2).
In infected secondary recipients, most Tfh cells maintained their
PD-1hiCXCR5hi phenotype 2.5 days after retransfer. In contrast,
Tfh cells strongly downregulated PD-1 and, to a lower extent,
CXCR5 in noninfected mice (Figure 2). Interestingly, such
a PD-1loCXCR5int phenotype has been recently correlated with
central memory T (Tcm) cells that derived from a BCL6-depen-
dent Tfh precursor population in a bacterial infection model
(Pepper et al., 2011). Reciprocally, YFP-CXCR5–BCL6loPD-1lo
non-Tfh cells retained their phenotype in noninfected mice while
a fraction acquired Tfh markers in infected mice (Figure 2). Thus,
maintenance of the Tfh cell phenotype is dependent on sus-
tained antigenic stimulation.
GC B Cells Are Required for the Maintenance of the
Tfh Cell Phenotype
Although recent studies have demonstrated that DCs can prime
naive T cells to differentiate into Tfh cells in the absence of
cognate B cell interactions, B cells become the major antigen-
presenting cell type for follicle-homing T cells at later stages of
the immune response (Ma et al., 2012). We therefore set out to
investigate the contribution of different B cell subsets in the
maintenance of PD-1hiCXCR5hi Tfh cells. To assess the role of
follicular B cells versus GC B cells, we treated OT-II/WT
mice with anti-CD20 on day +6 and day +8 after immunization
in order to not interfere with the initial immune response and
the establishment of GCs (Figure 3A). Anti-CD20 treatment
significantly reduced total spleen cellularity and the number of
CD20+CD19+B220+ non-GC B cells (Figure 3B). In contrast,
the number of GC B cells (CD19+B220+FAS+GL-7+) remainedImmunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc. 597
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Figure 1. Tfh and GC B Cell Numbers Are
Highly Interrelated and Positively Correlate
with the Amount of Available Antigen
(A–C) Naive OT-II cells were adoptively trans-
ferred into WT mice and allowed to equilibrate in
the host. Recipient mice were immunized intra-
peritoneally (i.p.) with 10 or 100 mg OVA in alum
16 hr later. Spleen cells were analyzed by flow
cytometry on day +7 after immunization. (A)
Representative contour plots show the
percentage of CD45.1+ OT-II cells among total
CD4+ T cells (7-AAD–B220–) and the percentage of
PD-1hiCXCR5hi Tfh cells among the transferred
OT-II cells. Total OT-II cell numbers and the
frequency of OT-II Tfh cells are quantified in the
bar graphs. Data are represented as mean ± SEM
with each dot indicating one mouse (n = 7–8).
(B) Representative contour plots show the
percentage of FAS+GL-7+ GC B cells among total
B cells (7AAD–CD19+B220+). The frequency of GC
B cells is quantified in the bar graph. Data are
represented as mean ± SEM with each dot indi-
cating one mouse (n = 7–8). (C) Graph shows the
correlation between GC B cell and Tfh cell
numbers. Data are representative of three inde-
pendent experiments.
(D) Naive OT-II cells were adoptively transferred
into WT hosts and all mice were immunized i.p.
with NP-OVA in alum 16 hr later. One group of mice
received additional injections of OVA in PBS
without adjuvant on day +4, +6, and +8 (chronic,
black bars), whereas the other group received
only PBS (acute, white bars). On day +9, spleen
cells were analyzed by flow cytometry for OT-II
cell numbers, percentage of OT-II Tfh cells,
and percentage of GC B cells. Gated on OT-II
cells (7-AAD–CD4+CD45.1+) or GC B cells (7-
AAD–CD19+B220+FAS+GL-7+). Data are repre-
sented as mean ± SEM with each dot indicating
one mouse (n = 6–9). Data are representative
of three independent experiments. See also
Figure S1.
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Tfh Cell Maintenance by Antigen and GC B Cellsunchanged upon anti-CD20 treatment, a finding that is consis-
tent with earlier reports (Gong et al., 2005). In addition, we did
not observe an immediate effect on splenic plasma cell
numbers (CD19intB220loCD138hi). Intriguingly, although the total
number of OT-II cells was slightly reduced in the anti-CD20-
treated animals, the percentage of OT-II cells with a Tfh cell
phenotype was slightly, albeit not significantly, increased in
mice treated with anti-CD20 antibody (Figure 3C). Thus,
non-GC B cells appear to be dispensable for the maintenance
of Tfh cells.
To address the role of GC B cells in the maintenance of
Tfh cells, we took advantage of our observation that in mice
expressing human diphtheria toxin receptor (DTR) and green
fluorescent protein (GFP) under the control of the CD11c
promoter (CD11c-DTR-GFP mice) (Jung et al., 2002), GFP was598 Immunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc.expressed not only in most DCs and in
a fraction of plasma cells, as previously
reported (Hebel et al., 2006; Jung et al.,
2002; Probst et al., 2005), but also ina fraction (21% ± 2%) of GC B cells, whereas it was virtually
absent in non-GC B cells (3.8% ± 0.2%) (Figure S2A). This
surprising finding was further supported by the observation
that GC B cells from immunized CD11c-YFP reporter mice (Lind-
quist et al., 2004) also had a high percentage of YFP+ cells, as
compared to marginal zone B cells and follicular B cells
(Figure S2B).
To limit CD11c-DTR transgene expression to the B cell
compartment, we generated mixed bone marrow (BM) chimeras
by transferring bone-marrow cells from CD11c-DTR mice and
B cell-deficient mMT mice into sublethally irradiated Rag1–/–
hosts (Figure 4A). Thus, all B cells in this system were of
CD11c-DTR donor origin, whereas DCs were of CD11c-
DTR-negative donor and host origin. Eight weeks after reconsti-
tution, BM-chimeric mice received naive OT-II cells and were
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Figure 2. Sustained Antigenic Stimulation
Is Required for the Maintenance of PD-1hi
CXCR5hi Tfh Cells
Naive LCMV-specific SMARTA cells from CD45.1+
Bcl6yfp/+ reporter mice were adoptively transferred
into naive WT mice. SMARTA Tfh (CXCR5+YFP-
BCL6+PD-1hi) and non- Tfh (CXCR5–YFP-
BCL6–PD-1int) cells were sorted from pooled
spleens of primary recipient mice (n = 5) on day +4
after i.p. LCMV infection, and cells were retrans-
ferred into secondary hosts that were either naive
or had been preinfected with LCMV 4 days before.
After 2.5 days in the secondary recipients, re-
transferred SMARTA cells recovered from the
spleens of the indicated mice were analyzed for
their Tfh cell phenotype by flow cytometry.
SMARTA cells were gated as 7AAD-CD45.1+
CD4+CD19 lymphocytes. Data are representative
of two independent experiments.
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Tfh Cell Maintenance by Antigen and GC B Cellschallenged i.p. with NP-OVA+alum. Injection of diphtheria toxin
(DTx) at the peak of the GC response (on day 6 and day 8) led
to a strong reduction in total GC B cell numbers per spleen by
day +9, whereas spleen cellularity, DC numbers, and non-GC
B cell numbers were not affected by DTx treatment (Figure 4B).
Importantly, the reduction of GC B cells was accompanied by
a significant reduction in the frequency of Tfh cells (measured
as either PD-1+CXCR5+ or ICOS+CXCR5+ T cells) in DTx-treated
hosts, while total OT-II cell numbers were largely unaffected
(Figure 4C). Rag1–/– mice reconstituted with CD11c-DTR-nega-
tive or WT bone marrow served as controls and did not show
any alterations in cell numbers of the analyzed cell types upon
DTx treatment (data not shown).
We also generated mixed BM chimeras by transferring BM
cells from CD11c-DTR-Cd3e–/– and Rag1–/– donor mice into
sublethally irradiated Rag1–/– hosts (Figure S2C). Reconstituted
T cell-deficient hosts were injected with naive OT-II cells and
challenged i.p. with NP-OVA+alum. Consistent with the results
obtained in the T cell sufficient bone marrow chimeric mice,
injection of DTx into CD11c-DTR-Cd3e–/–/Rag1–/– chimeric
mice at the peak of the GC response led to a strong reduc-
tion in total GC B cell numbers, which was accompanied by
a significant reduction in the frequency of Tfh cells, whereas
total OT-II cell numbers were largely unaffected (Figures S2D
and S2E).
Taken together, these data indicate that the maintenance of
Tfh cells is dependent on sustained cognate interactions with
GC B cells.
ICOS:ICOS-L and CD40:CD40L Interactions Are
Required for the Maintenance of Tfh Cells
To further characterize signaling pathways relevant to the main-
tenance of Tfh cells, we next sought to interfere with T cell-GC B
cell interactions in vivo through administration of antibodies that
block costimulatory signals. As in our previous experiments,
antibodies were administered starting approximately 1 week
after immunization in order to not interfere with the induction of
robust GCs (Figure 5A). Treatment of immunized OT-II/WT
mice with antibodies against ICOS-L (Figure 5B) or CD40L
(Figure 5D) significantly reduced PD-1+CXCR5+ Tfh cell and
FAS+GL-7+ GC B cell numbers. As seen before, there wasa direct correlation between the number of Tfh cells and the
number of GC B cells in individual mice that were either treated
with blocking antibodies to ICOS-L or CD40L (Figures 5C and
5E). Blockade of ICOS:ICOS-L and CD40:CD40L interactions
also led to a significant reduction of Tfh cell and GC B cell
numbers in lymphopenic OT-II/Cd3e–/–mice (Figure S3). Taken
together, these experiments indicate an important role for stim-
ulatory ICOS:ICOS-L and CD40:CD40L interactions in the recip-
rocal maintenance of GC B cells and the Tfh cell phenotype
during an established GC response.
Hypergammaglobulinemia and Polyreactive Antibodies
in Immunized OT-II/Cd3e–/– Mice
As a functional readout of Tfh cells, we analyzed the antibody
responses elicited by OVA immunization of OT-II/WT and
OT-II/Cd3e–/– mice. Both groups of mice mounted a strong
OVA-specific IgG response within the first 10 days after immuni-
zation with OVA+alum (821 ± 172 A.U. and 1192 ± 329 A.U.,
respectively, by day +10, Figure 6A). OVA-specific IgG
antibodies remained at high amounts for several weeks
afterward in OT-II/WT mice. In contrast, and in spite of the
high numbers of Tfh cells (on average 5-fold higher than in
WT hosts), OVA-specific IgG antibody amounts declined in
OT-II/Cd3e–/– mice, reaching levels that were less than ¼ of
that in OT-II/WT mice (675 ± 148 A.U. and 155 ± 49 A.U.,
respectively, by day +31). However, total serum IgG amounts
increased rapidly in OT-II/Cd3e–/– mice and remained sus-
tained for several weeks after immunization, reaching values
higher than those in OT-II/WT mice (Figure 6B). The increase
was most prominent for IgG1 and IgG2c, whereas IgG2b
amounts were slightly increased and IgG3 amounts developed
comparable to those measured in WT hosts. High amounts of
total IgE were found in OT-II/Cd3e–/– mice, whereas this
isotype was not detectable in WT hosts (Figure 6B). When
compared to sera from OT-II/WT mice, the sera from immu-
nized OT-II/CD3e–/– mice showed stronger nonspecific
binding to ELISA plates (Figure 6C). In addition, antibodies to
nuclear antigens (ANA) and ds-DNA could be detected in the
sera from immunized OT-II/CD3e–/– mice but not from WT
mice (Figures 6D and 6E), consistent with a fraction of these
antibodies being ‘‘sticky’’ and self-reactive.Immunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc. 599
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Figure 3. Non-GC B Cells Are Dispensable for the Maintenance of
the Tfh Cell Phenotype
(A) Schematic outline of experimental approach: naive OT-II cells were
adoptively transferred intoWTmice and immunized i.p. with OVA+alum. Hosts
were injected i.p. with 250 mg anti-murine CD20 antibody or anti-human CD20
antibody as isotype control on day +6 and +8. Spleens were dissected on
day +9 and analyzed by flow cytometry.
(B) Spleen cellularity, non-GC B cell numbers (gated as 7-AAD–CD19+B220+
FAS–GL-7–), GC B cell numbers (7-AAD–CD19+B220+FAS+GL-7+), and plasma
cell numbers (7-AAD–CD19intB220loCD138hi).
(C) OT-II cell numbers (7-AAD–CD45.1+CD4+) as well as percentage and
number of PD-1hiCXCR5hi OT-II cells. Data are represented as mean ± SEM
(n = 13). Data are representative of four independent experiments.
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Figure 4. GC B Cells Are Required for the Maintenance of Tfh Cells
(A) Schematic outline of experimental approach: BM chimeras were generated
by transferring 90% mMT and 10% CD11c-DTR bone-marrow cells into
sublethally irradiated Rag1–/– hosts. Eight weeks later, naive OT-II cells
were adoptively transferred into reconstituted hosts, followed by i.p.
immunization with NP-OVA+alum. One group of mice received 4 ng DTx per
gram of bodyweight on day +6 and +8, the other group received PBS
only as control. Mice were sacrificed on day +9 and spleen cells were
analyzed by flow cytometry for (B) total spleen cellularity, DC numbers
(7-AAD–CD19–CD3ε–CD11chiMHC-IIhi), non-GC B cell numbers (7-AAD–
CD19+B220+FASGL-7–), and percentage of GC B cells (7-AAD–CD19+
B220+FAS+GL-7+).
(C) Total OT-II cell numbers as well as percentages of PD-1+CXCR5+ and
ICOS+CXCR5+ OT-II Tfh cells. Data shown are mean ± SEM (n = 7–8 mice).
Data are representative of five independent experiments. See also Figure S2.
Immunity
Tfh Cell Maintenance by Antigen and GC B CellsThe increase in total IgG observed in lymphopenic CD3e–/–
hosts would be consistent with activation of B cells of irrelevant
specificity by the large numbers of OT-II Tfh cells. To provide
direct evidence for this phenomenon, we transferred OT-II cells
together with polyclonal B cells carrying a congenic marker
into SWHEL-Rag1
–/– host mice (all B cells specific for HEL) and
immunized the recipients with OVA+alum. As expected, a frac-
tion of the transferred polyclonal B cells became activated and
acquired a GC phenotype (Figure S4). Strikingly, also a fraction
of endogenous HEL-specific B cells became activated, acquired
a GC phenotype and produced class-switched IgG1 antibodies
(Figure S4).
Taken together, these results indicate that in lymphopenic
conditions Tfh cells can provide help to bystander B cells and
drive them into the GC reaction, thus leading to the production600 Immunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc.of isotype-switched antibodies of irrelevant specificities, in-
cluding poly-reactive and self-reactive antibodies.
DISCUSSION
In this study, we report several important findings. First, the
magnitude of the Tfh response is dictated by the amount of
antigen and directly correlates with the number of GC B cells.
Second, the Tfh cell phenotype is dependent on sustained
antigenic stimulation, as shown by the rapid loss of PD-1 and
high CXCR5 expression upon transfer into antigen-naive recipi-
ents. Third, and more importantly, maintenance of Tfh cells
during the GC reaction requires sustained interaction with GC
B cells. This conclusion is supported by the dramatic reduction
in Tfh cell numbers upon selective depletion of GC B cells,
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Figure 5. ICOS:ICOS-L and CD40:CD40L
Interactions Are Required for the Mainte-
nance of Mature Tfh Cells
(A) Schematic outline of experimental approach:
naive OT-II cells were adoptively transferred into
WT mice and immunized i.p. with OVA+alum.
Hosts were injected i.p. with blocking antibodies
or appropriate isotype controls starting around
1 week after immunization in order to not interfere
with initial priming of T cells and establishment
of GCs.
(B andC) Anti-iCOS-L (clone HK5.3) or appropriate
isotype control antibodies (250 mg per mouse)
were injected into OT-II/WT mice on day +6
and +8 after immunization, and spleens were
analyzed by flow cytometry on day +9. (B) shows
OT-II cell numbers (7-AAD–CD45.1+CD4+),
percentage of PD-1+CXCR5+ OT-II Tfh cells, and
percentage of GC B cells (7-AAD–CD19+B220+
FAS+GL-7+). Data are represented asmean ± SEM
(n = 5–8). (C) Graph shows the correlation between
GC B cell and OT-II Tfh cell numbers. Data are
representative of three independent experiments.
(D and E) Anti-CD40L (clone HK5.3) or appropriate
isotype control antibodies (200 mg per mouse)
were injected on day +6 and +8 after immuniza-
tion. Spleens were dissected on day +9 and
analyzed by flow cytometry as in (B) and (C). Data
are represented as mean ± SEM (n = 5–6) and are
representative of three independent experiments.
See also Figure S3.
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Tfh Cell Maintenance by Antigen and GC B Cellsbut not of non-GC B cells. The reduction of Tfh cell numbers
upon blockade of costimulatory pathways such as CD40:CD40L
and ICOS:ICOS-L in established GCs and the strong correlation
between Tfh and GC B cell numbers further highlight a tight
regulation between Tfh cells and GC B cells.
There is an ongoing debatewhether Tfh cells represent a sepa-
rate Th cell lineage or a transient activation state (Crotty, 2011;
Fazilleau et al., 2009; King, 2009). Our findings provide strong
evidence that the Tfh cell phenotype is of a transient nature.
They also reveal a substantial difference between Tfh cells and
other differentiated Th cells, such as Th1 and Th2 cells, which
can be maintained in the absence of antigen and polarizing cyto-
kines (O’Shea and Paul, 2010). Interestingly, the PD-1+CXCR5+
cells that have lost their Tfh phenotype upon transfer into
antigen-free hosts still maintained intermediate levels of
CXCR5, a phenotype that has been recently attributed to Tcm
cells (Pepper et al., 2011) and that may correspond to human
circulating Tfh cells (Breitfeld et al., 2000).
The finding that the Tfh cell phenotype is critically dependent
on sustained antigenic stimulation could explain recent observa-
tions that viral persistence preferentially directs Tfh cell genera-
tion in a model of chronic LCMV infection (Fahey et al., 2011)
and that Foxp3+ Treg cells convert into Tfh cells in Peyer’sImmunity 38, 596–60patches of lymphopenic CD3e–/– hosts
(Tsuji et al., 2009). In the latter
study, Foxp3+ Treg cells only converted
into Tfh cells in the gut, but not in
spleen and lymph nodes, an observation
that was attributed to the availability ofcertain Tfh cell-inducing cytokines, such as IL-6 (Tsuji et al.,
2009). Given that the Foxp3+ Treg cells were transferred into
nonimmunized CD3e–/– recipients, it is likely that the availability
of gut antigens, and thus sustained TCR stimulation, together
with the abundant proinflammatory signals, drove the preferen-
tial development of Tfh cells from Foxp3+ Treg cells in gut
Peyer’s patches.
Whether a sustained presence of Tfh cells in GC is beneficial
for the immune response remains to be established. Previous
studies have shown that strong virus-specific CD4+ T cell activa-
tion results in heightened polyclonal B cell activation, which
competes with virus-specific B cell activation and the formation
of neutralizing antibodies (Recher et al., 2004). As in the case of
these early reports, the bystander B cell activation that we have
observed in the present study seems to be the consequence of
the large numbers of highly stimulatory Tfh cells that develop in
lymphopenic mice. In conditions of polyclonal B cell activation,
cognate CD4+ T cell-B cell interactions may be less efficient
because antigen-specific B cells and plasma cells have to
compete for survival factors in lymphoid organs or in the bone
marrow, thus explaining the curtailed OVA-specific response.
Recent studies provided evidence for a follicular CD4+ Treg
cell population (defined as Tfr cell) that shares characteristics5, March 21, 2013 ª2013 Elsevier Inc. 601
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Figure 6. Bystander B Cell Activation, Hypergammaglobulinemia, and Production of Poly- and Self-Reactive Antibodies in Immunized OT-
II/Cd3e–/– Mice
(A and B) OT-II/WT and OT-II/Cd3e–/– mice were immunized i.p. with OVA+alum. Serum was collected at the indicated time points after immunization, and
OVA-specific IgG (A) or total Ig of the indicated isotypes (B) were measured by ELISA. Data are represented as mean ± SEM (n = 4–5).
(C) Total serum IgG was measured by ELISA from samples collected on day 28 and different IgG concentrations were applied to uncoated, BSA-blocked ELISA
plates. Bound IgG antibody levels were determined by ELISA. O.D. values are shown as mean ± SEM (n = 5).
(D) Anti-nuclear antibodies (ANA) and anti ds-DNA antibodies were measured in the sera of day +25 OT-II/WT and OT-II/Cd3e–/– immunized mice. Data are
represented as mean ± SEM (n = 4–5).
(E) Sera (1:1,000) from day +25 OT-II/WT and OT-II/Cd3e–/– immunized mice (primed) or OT-II/Cd3e–/– mice immunized with PBS+alum (not primed)
were analyzed for the presence of ANA by incubation on HEp-2 slides or murine stomach sections. Mouse IgG ANA were detected by Alexa Fluor-488 goat anti-
mouse IgG F(ab)2 fragments. Nuclei were counterstained with DAPI. Data are representative of three independent experiments that yielded similar results. See
also Figure S4.
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Tfh Cell Maintenance by Antigen and GC B Cellsof natural Treg and Tfh cells and restrains excessive Tfh and
GC B cell responses (Alexander et al., 2011; Chung et al.,
2011; Linterman et al., 2011; Wollenberg et al., 2011). Further
studies will be required to address the role of Tfr cells or other
T cell populations in the dysregulated antibody response
observed in lymphopenic mice.
One interesting finding of our study is that CD11c-DTR
transgene expression by GC B cells rendered these cells highly
susceptible to DTx-mediated depletion. Several authors have
cautioned that the relatively broad expression of CD11c
makes it essential to carefully plan and interpret experiments
that make use of CD11c reporter mice (Murphy, 2011; Probst
et al., 2005). Thus, we took special care to generate BM
chimeras with restricted CD11c-DTR expression within the B
cell lineage. It should be noted that not all GC B cells stained
positive for GFP or YFP in the two different mouse strains
used for these experiments. We speculate that CD11c might
be expressed at different stages in the life of GC B cells, for
instance during their passage through the dark or light zones.
Nevertheless, GC B cell depletion by this method was highly602 Immunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc.selective and resulted in a remarkable reduction in both GC B
cell and Tfh cell numbers. Future experiments should be aimed
at further dissecting the precise kinetics of CD11c expression
in GC B cells.
Besides their well-established role in driving antibody produc-
tion, Tfh cells are emerging as central intermediaries of other
T helper cell-mediated immune responses. Tfh-like transitions
of activated T cells have been correlated with Th1 effector cell
differentiation (Nakayamada et al., 2011; Oestreich et al., 2012)
and also with the generation of cells with a Tcm phenotype
(Pepper et al., 2011). Interestingly, although anti-CD20 treatment
has been shown to ameliorate disease severity in several
autoimmune diseases, such as in multiple sclerosis (Hauser
et al., 2008), it does not necessarily reduce autoantibody
levels in these patients. Given that GC B cells are only ineffi-
ciently depleted by anti-CD20 treatment, it may be possible
that the anti-CD20 treatment selectively interferes with early
T cell-B cell interactions involved in Th1 and Tcm cell generation,
whereas established Tfh cells could remain an important
driver of autoimmune progression in this situation.
Immunity
Tfh Cell Maintenance by Antigen and GC B CellsIn conclusion, our data identify antigen-presenting cells and
costimulatory molecules that are required for the maintenance
of Tfh cells and suggest a link between overwhelming Tfh cell
responses and the development of dysregulated humoral
immune responses. These data are not only relevant in the
context of emergingmodels of Tfh cell development and function
but also suggest that therapies aiming at specifically disrupting
Tfh cell-GC B cell interactions may be useful in the treatment
of antibody-mediated autoimmune diseases, such as rheuma-
toid arthritis and systemic lupus erythematosus. Furthermore,
our findings may have implications for the treatment of patients
with congenital defects in lymphocyte homeostasis and patients
suffering from diseases involving lymphopenia, such as HIV
infection (Lindqvist et al., 2012) or certain tumors.
EXPERIMENTAL PROCEDURES
Mice
SMARTA (Oxenius et al., 1998), SWHEL (Phan et al., 2003), and YFP-BCL6 (Ki-
tano et al., 2011) mice have been described previously. OT-II (004194), mMT
(002288), CD11c-DTR (004509), CD11c-YFP (008829), and Rag1–/– (002216)
mice were obtained from The Jackson Laboratory. Cd3e–/– mice, which lack
all T cells but have organized lymphoid organ structures and normal B cell
development, have been described previously (Malissen et al., 1995). These
mice have basal serum IgM levels comparable to WT mice but lack IgG1,
have reduced levels of IgG2b, IgG2c, and IgA, and increased levels of IgG3
(data not shown). All OT-II donor mice were bred and maintained on a
Rag1–/– background. SMARTA mice were maintained on a WT background.
For identification of transferred cells within hosts, donor mice were bred
onto homo- or heterozygous CD45.1 allele backgrounds. For B cell-specific
CD11c-DTR BM-chimeras, 90% bone-marrow cells from mMT or Rag1–/–
donors and 10%bonemarrow cells fromCD11c-DTR donors were transferred
into sublethally irradiated Rag1–/– hosts. Chimeras were used 2 months after
successful reconstitution. All mice were bred and maintained under specific
pathogen-free conditions. Animals were treated in accordance with guidelines
of the Swiss Federal Veterinary Office or the Institutional Animal Care and Use
Committee guidelines of the University of California, San Francisco, and
experiments were approved by the Dipartimento della Sanita` e Socialita` of
Canton Ticino.
Adoptive Cell Transfers
Single-cell suspensions were prepared by mincing spleens and peripheral
lymph nodes between the frosted ends of glass slides, and cell suspensions
were filtered through fine mesh. CD4+ T cells were first enriched with the
Naive T Cell Isolation Kit (Miltenyi Biotec) or by positive selection with anti-
CD4-FITC antibodies (clone RM4-5) followed by anti-FITC microbeads
(Miltenyi Biotec). Naive CD4+CD8–CD44loCD62LhiCD25– T cells were then
sorted on a FACSAria cell sorter (BD Biosciences) to >99% purity. Low
numbers of OT-II cells (153 104 cells per mouse) were injected intravenously
(i.v.) and allowed to equilibrate within the host for 16–24 hr before immuniza-
tion. For infection experiments, 1 3 106 naive SMARTA cells from Bcl6yfp/+
reporter mice were transferred into congenic primary recipients, followed by
i.p. infection with LCMV the next day. CD45.1+ Tfh (CXCR5+YFP-BCL6hi)
and non-Tfh (CXCR5–YFP-BCL6lo) SMARTA cell populations were sorted
from the pooled spleens on day +4 and retransferred into secondary hosts
that had been preinfected with LCMV 4 days before or left untreated and all
hosts were analyzed 2.5 days later.
Immunizations, Infections, and Diphtheria Toxin Treatment
Mice were immunized intraperitoneally with endotoxin-free, >98% purity
OVA (Endograde OVA; Profos), KLH (Calbiochem), NP-OVA, or NP-KLH
(Biosearch Technologies), in combination with 10 mg monophosphoryl lipid
A (Sigma-Aldrich) or Imject Alum (Pierce Biotechnology) as adjuvants. For
viral infections, mice were injected i.p. with 2 3 106 PFU LCMV Armstrong
strain. For depletion of CD11c-DTR-sensitive cells, diphtheria toxin from
Corynebacterium diphtheriae (Sigma-Aldrich) was diluted in 200 ml PBSaccording to the weight of the mice (4 ng per kg of body weight) and
injected i.p.
In Vivo Antibody Treatments
Anti-CD40L (hamster IgG, clone MR-1), anti-iCOS-L (rat IgG2a, clone HK5.3;
with permission from Hideo Yagita), and appropriate isotype controls were
purchased from Bio X Cell. Anti-mouse CD20 (mouse IgG1, clone 18B12)
and anti-human CD20 (mouse IgG1, clone 2B8, used as isotype control) anti-
bodies were kindly provided by Robert Dunn (Biogen Idec). Recipient mice
were injected i.p. with 200250 mg of respective antibodies in PBS every
2 days starting approximately 1 week after immunization in order to not inter-
fere with the initiation of GCs. If not otherwise stated, flow cytometric analyses
were usually performed on day +9 after immunization.
Flow Cytometry
The following antibodies or streptavidin, conjugated to biotin, FITC, Alexa
Fluor (AF) 488, PE, PE-Cy7, PerCP-Cy5.5, APC, AF647, APC-Cy7,
APC-AF750, APC-H7, Pacific Blue, eFluor450, Qdot605, or Pacific Orange
were purchased from BD Biosciences, eBioscience, Biolegend, or Invitrogen:
CD3ε (clone 145-2C11), CD4 (RM4-5), CD8a (53-6.7), CD11c (N418), CD19
(1D3), CD25 (7D4), CD28 (37.51), CD62L (MEL-14), CD44 (IM7), CD45.1
(A20), CD45.2 (104), PD-1 (RMP1-30 or J43), B220 (RA3-6B2), FAS (Jo2),
GL-7, IgD (11-26c), CD21 (7E9), CD23 (B3B4), MHC class II (M5/114.15.2),
and CXCR5 (2G8). PNA was used either conjugated to AF647 (Invitrogen)
or to biotin (Vector Laboratories). Dead cells were excluded with 7-AAD
(eBioscience). In some experiments, certain cell types were excluded in
a dump channel with PerCP-conjugated anti-CD4, CD8, CD11b, Gr-1, F4/
80, and/or B220. Routine 7- to 8-color flow cytometry was performed on a
FACSCanto II or LSR II (BD Biosciences) and data were evaluated using
FlowJo software (TriStar).
Quantitative Real-Time PCR
Transferred OT-II T cells were enriched from the spleen of recipient mice using
anti-CD45.1-FITC antibodies and anti-FITC microbeads (Miltenyi Biotec) and
further sorted by FACS into CXCR5+ and CXCR5– cell fractions. RNA was
prepared using TRIzol LS reagent (Invitrogen), transcribed into cDNA, and
analyzed as described before (Reboldi et al., 2009).
ELISA
ELISA was performed as previously described (Kingston et al., 2009). In brief,
96-well half-area plates (Costar) were coated overnight with 5 mg/ml anti-ig
antibodies or 10mg/ml antigen in PBS at 4C. Plates were blocked with 1%
BSA/PBS, and serial dilutions of sera in 1% BSA/PBS were applied to the
plates and incubated at RT. Alkaline phosphatase-conjugated anti-mouse Ig
isotype-specific antibodies (Southern Biotechnologies) followed by pNPP
substrate (Sigma-Aldrich) were used as detection reagents. Absorbance
was measured at 405 nm with a microplate reader (Molecular Devices)
and absolute values were calculated according to Ig standards (Southern
Biotechnologies) or reference serum from hyperimmunized mice (expressed
in arbitrary units, AU). IgE levels were measured with rat anti-mouse IgE
(clone R35-118) as capture antibody and biotinylated rat anti-mouse IgE (clone
R35-72) as detection antibody (both from BDBiosciences), followed by avidin-
HRP (Sigma-Aldrich) and ABTS according to the manufacturer’s instructions.
Autoantibody Detection
Commercially available HEp-2 and mouse tissue slides (Orgentec) were
used for the detection of autoantibodies in the sera of immunized mice with
AF488-conjugated goat anti-mouse IgG F(ab)2 fragments (Invitrogen). Nuclei
were counterstained with DAPI (Sigma). Images were acquired on a confocal
Leica TS5 system. Images were processed with Photoshop (Adobe) software
without nonlinear operations. Anti-dsDNA andANA IgGwere determined using
commercial kits from Alpha Diagnostic according to the manufacturer’s
instructions.
Statistics
Data were analyzed with Prism 5 (GraphPad Software) using the two-
tailed nonparametric Mann-Whitney U test. Graphs show the mean ± SEM.Immunity 38, 596–605, March 21, 2013 ª2013 Elsevier Inc. 603
Immunity
Tfh Cell Maintenance by Antigen and GC B Cells*, p < 0.05; **, p < 0.01; ***, p < 0.001. The correlation coefficient r and the
respective p value were also calculated with Prism 5.SUPPLEMENTAL INFORMATION
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